Antibody-mediated transduction of p53 selectively kills cancer cells.

Authors:
  • JHJames E. Hansen
    James E. Hansen
  • GCGrace Chan
    Grace Chan
  • RWRika Wakelin
    Rika Wakelin
  • SCSophia S. Chang
    Sophia S. Chang
  • EHEmil Heinze
    Emil Heinze
  • CMCarl W. Miller
    Carl W. Miller
  • PKPhillip H. Koeffler
    Phillip H. Koeffler
  • FYFusheng Yang
    Fusheng Yang
  • GCGreg M. Cole
    Greg M. Cole
  • YMYoon S. Min
    Yoon S. Min
  • RNRobert N. Nishimura
    Robert N. Nishimura

Abstract
Some human cancers are caused by functional defects in p53 that are restored by gene therapy with wild-type p53. To circumvent the use of viral vectors, we reconstituted cancer cell lines with p53 by protein transduction. A fusion protein was produced from cDNA constructed from the Fv fragment of an antibody that penetrates living cells and wild-type p53 (Fv-p53). Fv-p53 penetrated and killed cancer cells that do not express p53. Additionally, Fv-p53 killed cancer cells that were malignant as a result of mutations within p53, nuclear exclusion of p53 and over-expression of MDM2. Non-specific toxicity was excluded by showing that Fv-p53 penetrated but did not kill primary cells and cancer cells unresponsive to p53. Fv fragments alone were not cytotoxic, indicating that killing was due to transduction of p53. Fv-p53 was shown to penetrate cancer cells engrafted in vivo. These results support continued efforts to evaluate the potential efficacy of Fv-p53 for the treatment of certain cancers in vivo.